课件：ARBs在高血压治疗中的地位.ppt

* 这是安博诺中国四期临床研究结果，分别列出服用安博诺2周、4周和8周后患者的达标率（目标血压140/90mmHg），我们可以看到在服用2周达标率即达到77％，而8周后的达标率90%。 背景： 安博诺四期临床（安博诺治疗中国原发性高血压病达标率分析）是多中心、开发、单一治疗组的研究，全国共有32家三甲医院参加，共入组患者920例。文章发表在2005年7月的《中华心血管病杂志》上，作者是北京大学人民医院的孙宁玲教授。 * * * 后面内容直接删除就行 资料可以编辑修改使用 资料可以编辑修改使用 资料仅供参考，实际情况实际分析 主要经营：课件设计，文档制作，网络软件设计、图文设计制作、发布广告等 秉着以优质的服务对待每一位客户，做到让客户满意！ 致力于数据挖掘，合同简历、论文写作、PPT设计、计划书、策划案、学习课件、各类模板等方方面面，打造全网一站式需求 * * The principal finding of VALUE was that, for the primary composite endpoint of cardiac mortality and morbidity, there were no significant differences in these high-risk patients treated with valsartan- or amlodipine-based regimens.1 This was observed despite significant differences in achieved blood pressures. In a recent meta-regression analysis based on 30 hypertension trials with 149,407 patients, differences in achieved SBP were found to largely account for cardiovascular outcomes.2 1. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial. Lancet. 2004;363. 2. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-1076. * In a study led by Kassler-Taub, 532 patients with mild-to-moderate hypertension completed an 8-week, double-blind period in which they received 100 mg losartan, 150 mg irbesartan,300 mg irbesartan, or a placebo. All active treatments reduced BP significantly (p0.001) versus placebo at all time points. A greater antihypertensive effect of irbesartan 300 mg once daily compared with losartan 100 mg once daily was present throughout the study. At Week 8, reductions from baseline in trough seated diastolic BP (SeDBP), the primary endpoint of the trial, were significantly greater with irbesartan 300 mg, compared with losartan 100 mg by 3.0 mmHg (-11.7 vs. -8.7 mmHg; p0.01). The difference in SeDBP between these 2 groups was also sta